CNS Pharmaceuticals, Inc.

NasdaqCM:CNSP Stock Report

Market Cap: US$6.6m

CNS Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:CNSP Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
01 Feb 24BuyUS$50,000John ClimacoIndividual3,333.32US$15.00
01 Feb 24BuyUS$20,000Christopher DownsIndividual1,333.32US$15.00
01 Feb 24BuyUS$10,000Jerzy GumulkaIndividual666.66US$15.00
01 Feb 24BuyUS$10,000Carl EvansIndividual666.66US$15.00

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of CNSP?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders535,8670.932%
Private Companies573,5010.998%
Institutions1,639,6822.85%
General Public54,737,65695.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54664.4%.

Top Shareholders

Top 25 shareholders own 4.78% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
1.85%
Armistice Capital LLC
1,062,287US$122.1k11,200%no data
1%
Cortice Biosciences Incorporated
573,368US$65.9k0%no data
0.89%
Robert Forster
512,500US$58.9k0%no data
0.35%
Geode Capital Management, LLC
203,180US$23.3k35,900%no data
0.32%
UBS Asset Management AG
181,866US$20.9k6,820%no data
0.21%
Virtu Financial LLC, Asset Management Arm
122,876US$14.1k0%no data
0.049%
Goldman Sachs Group, Investment Banking and Securities Investments
28,197US$3.2k0%no data
0.04%
Jane Street Group, LLC, Asset Management Arm
23,160US$2.7k0%no data
0.028%
Tower Research Capital Europe Limited
16,298US$1.9k14,100%no data
0.021%
John Climaco
11,912US$1.4k3.48%no data
0.0091%
Christopher Downs
5,218US$599.83.72%no data
0.0055%
Jerzy Gumulka
3,162US$363.336.7%no data
0.002%
The Vanguard Group, Inc.
1,167US$134.10%no data
0.0017%
Jeffry Keyes
976US$112.3675%no data
0.0012%
Carl Evans
669US$76.60%no data
0.0011%
Faith Charles
626US$72.02,220%no data
0.0007%
Aspire Private Capital, LLC
400US$46.20%no data
0.00055%
Bettina Cockroft
318US$36.3657%no data
0.00045%
Sandra Silberman
260US$29.752.1%no data
0.00041%
Bank of America Corporation, Asset Management Arm
234US$27.123,300%no data
0.00023%
Houston Pharmaceuticals, Inc.
133US$15.20%no data
0.00021%
Andrzej Andraczke
119US$13.90%no data
0.00019%
Amy Mahery
107US$12.5664%no data
0.00001%
Blackstone Alternative Investment Advisors LLC
8US$0.7-109%no data
0.00001%
Wells Fargo & Company, Securities and Brokerage Investments
4US$0.70%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 07:49
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CNS Pharmaceuticals, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew CrossAlliance Global Partners
Bruce JacksonBenchmark Company
Robert LeBoyerLadenburg Thalmann & Company